Optomed Oyj Class A · OMXHEX:OPTOMED
Optomed Oyj Class A — Q1 2025 Earnings Presentation
11 slides from Optomed Oyj Class A's earnings presentation, May 6, 2025
Slide 1: Optomed Q1 2025
Optomed Q1 2025 6th May 2025 Juho Himberg, CEO Sakari Knuutti, CFO
Slide 2: Highlights Q1
Highlights Q1 1. 2. 3. Devices segment Software Positive cashflow from revenue up by 72% Segment grew operating activities driven by the US steadily 2.4% continued and strong cash position
Slide 3: Q1-2025 Key Figures
Q1-2025 Key Figures STRONG QUARTER - Q1 CONTINUED THE GOOD TREND OF Q4 Q1/2025 Q1/2024 Change Revenue 4,021 3,327 20.9% Gross profit 2,693 2,213 21.7% Gross margin 67.0% 66.5% +5pps Adjusted EBITDA -737 -648 -13.7% Adjusted EBITDA margin -18.3% -19.5% +12pps Net profit / loss -1,581 -1,090 -44.9% Ea
Slide 4: Segment highlights
Segment highlights OPT@MED
Slide 5: Devices Segment Q1-2025
Devices Segment Q1-2025 OUR TOPLINE GREW 72 % Q1/2025 Q1/2024 Change Revenue surged driven by the 1. US sales growth. Revenue 1,526 890 71.5% Aurora AEYE continues to scale Gross profit 897 516 74.0% 2. steadily in both adoption and usage. Gross margin 58.8% 58.0% +8pps Our next generation camera EB
Slide 6: Software Segment Q1-2025
Software Segment Q1-2025 THE SOFTWARE SEGMENT CONTINUED WITH ITS STEADY CONTRIBUTION Q1/2025 Q1/2024 Change Healthcare revenue increased 1. but the increase was partly offset by the decline of non-healthcare Revenue 2,496 2,437 2.4% consulting revenue. Gross profit 1,796 1,697 5.8% The staff cost in
Slide 7: Cash Flow Q1-2025
Cash Flow Q1-2025 CASH POSITION AT EUR 9.7 MILLION Q1 2025 Q1 2024 Loss for the financial year -1,581 -1,090 • Positive net cash from operating Cash flows before change -692 -596 in net working capital activities supported by changes in net working capital Change in net working capital 1,101 127 Cas
Slide 8: Outlook 2025
Outlook 2025 Outlook 2025: Key items supporting our growth: • Increased adoption of AI-powered screening solutions, Optomed expects its full particularly in the U.S. following the FDA clearance year 2025 revenue to grow • New partnerships and collaborations with healthcare providers strongly compare
Slide 9: Summary
Summary • Strong start for the year 2025 • Aurora AEYE continues to scale steadily in both adoption and usage. • New product launch expected in Q2 • Optomed expects its full year 2025 revenue to grow strongly compared to 2024.
Slide 10: Appendix
Appendix OPT@MED
Slide 11: Balance Sheet
Balance Sheet 31 March 2025 31 March 2024 • Equity ratio of 73.0 (69.5) ASSETS Goodwill percent 4,256 4,256 Development costs 8,487 7,996 Other intangible assets 1,323 1,680 • Total borrowings of EUR Total intangible assets 14,066 13,932 2.1 (3.1) million Total tangible assets 857 652 Total non-curr